Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo

Eli Lilly used the American Diabetes Association’s annual meeting to announce that its investigational triple agonist retatrutide can treat the conditions obesity drives, beyond the excess weight itself. Detailed Phase 3 results from the TRIUMPH-1 program showed the once-weekly GIP, GLP-1 and glucagon agonist cut moderate-to-severe obstructive sleep apnea severity by up to 60.6% and… The post Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo appeared first on Drug Discovery and Development.

Continue reading →